Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial

  • K. Kent Chevli
  • , Neal D. Shore
  • , Andrew Trainer
  • , Angela B. Smith
  • , Daniel Saltzstein
  • , Yaron Ehrlich
  • , Jay D. Raman
  • , Boris Friedman
  • , Richard D'Anna
  • , David Morris
  • , Brian Hu
  • , Mark Tyson
  • , Alexander Sankin
  • , Max Kates
  • , Jennifer Linehan
  • , Douglas Scherr
  • , Steven Kester
  • , Michael Verni
  • , Karim Chamie
  • , Lawrence Karsh
  • Arnold Cinman, Andrew Meads, Soumi Lahiri, Madlen Malinowski, Nimrod Gabai, Sunil Raju, Mark Schoenberg, Elyse Seltzer, William C. Huang

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)61-68
Number of pages8
JournalThe Journal of urology
Volume207
Issue number1
DOIs
StatePublished - Jan 1 2022

ASJC Scopus Subject Areas

  • Urology

Keywords

  • clinical trial
  • mitomycin
  • phase II
  • urinary bladder neoplasms

Cite this